1	Study protocol for a multi-centre stepped-wedge cluster randomised trial to explore the
2	usability and outcomes among young people living with HIV in Kiambu and Kirinyaga
3	counties of Kenya, using an online health portal.
4	Eric Nturibi ^{1*¶} , Jared Mecha ^{1¶} , Elizabeth Kubo ^{1¶} , Albert Orwa ^{1¶} , Florence Kaara ^{1&} , Faith
5	Musau ^{1&} , Christine Wamuyu ^{1&} , Justus Kilonzi ^{2&} , Randeep Gill ^{3¶} , Sanne Roels ^{3&}
6	Correspondence to Eric Nturibi, Email: <u>ericmugambi@gmail.com</u> , Tel: +254-722758767
7	Affiliations
8	1. Department of Clinical Medicine and Therapeutics, University of Nairobi School of
9	Medicine, Nairobi, Kenya
10	2. Savannah Informatics LTD, Kenya
11	3. Janssen Pharmaceutica NV
12	*Corresponding author
13	Email: <u>ericmugambi@gmail.com</u>
14	[¶] These authors contributed equally to the work
15	&These authors also contributed equally to the work
16	Short title: Online health portal use in youth with HIV: a stepped wedge cluster RCT
17	ABSTRACT
18	Introduction: While the incidence of HIV declines in most age groups globally, it continues to
19	rise among adolescents and young adults who also experience a higher rate of HIV-related
20	deaths. These tech-savvy individuals might benefit from an online patient portal aimed at

21 increasing awareness, building skills, and promoting patient activation – the willingness and 22 capacity to independently manage their health. However, the impact of such portals on young 23 HIV patients in Kenya remains uncertain. Methods and analysis: HIV patients aged 15-24 with 24 smartphone access will participate in a 12-month stepped wedge cluster randomized trial. The 25 main focus will be the portal's effect on patient activation, with secondary outcomes being self-26 reported adherence, viral suppression, and social involvement. The study also aims to understand 27 the portal's development, implementation, functionality, usability, and cost. From 47 28 antiretroviral therapy (ART) sites with electronic medical recording systems, 16 clusters of 30 29 participants each will be formed. These clusters, over 12 months, will be randomized into 3 30 intervention sequences every 3 months. Baseline measurements, covering patient activation, 31 adherence, viral load, and social engagement, will be recorded over two weeks, with subsequent 32 checks at 3, 6, and 12 months. Data will be analyzed using generalised linear mixed models. 33 **Ethics and dissemination:** The protocol has received approval from the AMREF Health Africa 34 Ethics & Scientific Review Committee (ESRC) and local governments. Findings will be shared 35 through stakeholder forums, conferences, publications, and media.

36 Author Summary

- 37 What is the issue? HIV infections among teenagers and young adults are increasing, particularly
- in Kenya. Given their technological inclination, an online portal might help them manage their
- 39 health. The effectiveness of this approach remains uncertain.
- 40 What are our actions? We are running a year-long study in Kenya with HIV-positive
- 41 individuals aged 15 to 24 who have smartphones. The goal is to see if the portal aids their health
- 42 management. We're assessing health readiness, medication adherence, HIV control, and social
- 43 connection. The study involves groups from 47 HIV treatment centers, with new groups
- 44 engaging with the portal every three months.

45 What are our assessment methods?

46 We will use statistical methods to gauge the portal's impact on health management.

47 Is the study approved?


- 48 Yes. It has endorsements from AMREF Health Africa and local governments. Results will be
- 49 shared with the community, at conferences, in scientific journals, and in the media.


50 Introduction

51 Of the 37.7 million persons living with HIV (PLHIV) worldwide in 2020, 25.3 million were 52 resident in sub-Saharan Africa (SSA), where 460,000 of the 680,000 global AIDS related deaths 53 (ARDS) also occurred (UNAIDS, 2021). In 2020, 400,000 adolescents and young persons (AYP) 54 were newly infected with HIV, of whom 150,000 were aged 10 to 19(1). Globally, whereas new 55 HIV infections are declining for other age groups, they are increasing in the adolescent age group 56 (10-19vrs), who also contribute disproportionately to ARDs(2). In 2020, there were an estimated 57 1.4 million PLHIV in Kenya including 160,000 young persons (ages 15-24). Of the estimated 58 33,000 new infections, 35% occurred in young persons (ages 15-24)(3). With 59.24 million 59 connections as at January 2021, Kenya had a mobile penetration of 108.9% and an internet 60 penetration of 40% (21.75 million), including 11 million social media users(4). According to a 61 report by the United Nations, young people in low and middle income countries (LMICs) are 62 nearly three times more likely to be using the internet than the general public(5). A recent review 63 of digital health solutions (DHS) for engaging PLHIV decried the lack of published interventions 64 targeting the more than 4 million young people aged 15-24 living with HIV globally, despite 65 their identification as a "critical group experiencing multiple barriers to engagement in care."(6). Patient health portals are therefore particularly attractive in this vulnerable population who are 66 67 likely to welcome digital health solutions more readily than other age groups. 68 The functionalities proposed in the digital health platform, $myCareHub^{TM}$, have been carefully

designed to incorporate mechanisms identified as critical for outcome achievement (fig 1) (7)
and are based on the COM-B framework (fig 2) that links behaviour to capability, opportunity,
and motivation (8).

72 Figure 1: Mechanisms of patient activation (adapted from Otte-Trojel, de Bont (7))






73 *Figure 2: COM-B theoretical framework for behaviour change*

74 The design was heavily influenced by the views and preferences of the intended users

- 75 (unpublished data) with inputs from an experienced team of AYP resource persons.
- 76 myCareHubTM will be accessible on internet enabled mobile phones through a dedicated
- password to ensure security and confidentiality of data. It is designed to offer a wide array of
- 78 services to healthcare providers (HCPs) and patients (fig 3).
- 79



80 Figure 3: Diagrammatic representation of myCareHubTM and functions available to use.

- 82 This study seeks to establish whether an online patient health portal, myCareHubTM improves
- 83 AYP activation and consequent engagement in HIV care and treatment. Further, in line with
- 84 World Health Organization (WHO) guidelines for mobile health evidence reporting and
- 85 assessment (mERA), the study will explore quality, fidelity, and coverage of the platform, as
- 86 well as key program indicators (fig 4)(9); features that are often overlooked in published studies.

	STAGE: Pre-prototype Prototype Pilot Demonstration Scale-up	
	Functionality Fidelity	
	Stability Quality	
ype	MONITORING (Are we doing things right?)	Implementation
Prototype	EVALUATION (Are we doing the right things?)	lemer
-	Usability Efficacy Effectiveness Implementation research	aml
	Feasibility Economic/financial evaluation	
	Increasing users (10-100 at prototype; 100-1000 pilot; 10000+ demonstration; 100,000+	
	Maturity over time	

Figure 4: Intervention life cycle of a digital intervention

- 88 The findings of this study will inform HIV programming for young persons and other vulnerable
- 89 populations, shift health policy on digital health solutions and contribute substantially to the
- 90 elimination of AIDS as a global threat by 2030.
- 91 Methods and Analysis

92 Setting

- 93 The University of Nairobi Central Kenya Response: Integration, Strengthening and
- 94 Sustainability Plus (CRISS Plus) project is a 5-year PEPFAR-funded HIV prevention, care &
- 95 treatment project in partnership with Kiambu & Kirinyaga county governments. The project
- 96 currently supports HIV related activities at 78 public facilities. Forty-seven (47) facilities have an
- 97 electronic medical records (EMR) system. The 47 EMR sites will be clustered based on
- 98 geographical proximity loosely coinciding with sub county territorial assignment of the facilities
- and covering 15 out of the 17 supported sub-counties. The largest treatment site will constitute

- 100 the 16th cluster on account of the large number of adolescent and young people enrolled in its
- 101 antiretroviral treatment (ART) program.
- 102 At study inception, the program provided ART for 38,079 PLHIV, of whom 3,459 (9%) were
- 103 AYP. The target population for the study will be AYP (ages 15-24 years) enrolled in supported
- 104 clinics. Eighty-nine per cent (89%) of the target population are enrolled in the 47 EMR sites.

105 Study design

- 106 We plan to conduct a multicentre stepped wedge cluster randomised trial to assess whether a
- 107 bespoke patient health portal, myCareHub[™], can improve patient activation and clinical
- 108 outcomes among consenting individuals aged 15 to 24 living with HIV and attending the ART
- 109 clinic at one of 47 EMR-enabled treatment centres (table 1). Caregiver consent will be obtained
- 110 for participants under the age of 18.

Table 1: PICOT Framework	
Population	Adolescents and young persons (15-24 years
	old) attending an EMR-enabled Anti-
	Retroviral Treatment (ART) site and with
	ready access to a smartphone
Intervention	Making a patient health portal with several
	functionalities available
Comparator	Standard of care patient engagement
	strategies
Outcome	Patient activation as the primary outcome.
	Secondary outcomes: viral load, social
	engagement measures, adherence, and portal
	use features
Time	15 months total, the first three being control,
	with 3-month intervals between sequences,
	and measurements taken over a 2-week
	period. Once all clusters cross over from
	control to intervention, an observation
	period of 6 months will follow.

- 112 In total, a minimum sample of 480 adolescents and young persons will be recruited into 16
- 113 clusters using a stepwise design (table 2) with intervals of three months between successive
- 114 steps.

Time TO: 2wks T1: Mo 1 - 3 2wks T2: Mo 4 - 6 2wks T3: Mo 7 - 9 2wks T4: Mo 10-12 2wks

115 Table 2: Study design: Cluster randomized, stepped wedge design with 16 clusters and 3 sequences.

116 *NB: the 3rd sequence is prolonged to allow for the last stratum to complete six months which is the recommended minimum duration to*

117 assess for patient activation as per the reviewed literature.

- 118 Stratification of clusters will be conducted based on size, sex/gender mix and viral load
- suppression (table 3) to come up with comparable blocks of clusters prior to randomisation (table
- 120 4).

Sub-county	Number of AYPs	Size Strata	*VLS 15-19	VLS 20-24	Cohort retention	Males (%)
Thika town	632	Large	80%	90%	89%	41%
Ruiru	330	-	84%	89%	68%	25%
Kiambu town	205	Medium	86%	89%	100%	32%
K Central	176	-	86%	90%	84%	55%
Gatundu South	166	-	61%	90%	50%	40%
Juja	146	-	91%	82%	67%	35%
Kiambaa	123	-	87%	91%	100%	27%
Kirinyaga South	116	_	91%	87%	88%	53%
Githunguri	113		85%	89%	100%	27%
Kabete	110	-	94%	94%	100%	23%
Gatundu North	107		92%	89%	100%	40%
Limuru	103		90%	100%	100%	35%
Kirinyaga West	88	Small	81%	92%	74%	37%
Kikuyu	73	-	100%	90%	100%	16%
Kirinyaga East	58		100%	86%	87%	57%
Lari	51		100%	91%	100%	23%
Kirinyaga North	50		60%	68%	88%	48%

121 Table 3: Sub-counties by key attributes

122 Clusters within each comparable block (stratum) will be randomly assigned to one of the three

123 sequences for time of crossover from control to intervention using a computer-generated list of

124 random numbers. Clusters will receive the intervention in groups of five and six. There will be a

125 total of 3 intervention sequences – the third extending 6 months. Each cluster will begin in the

126 control period and eventually receive the intervention, with the order of crossover being

127 randomly determined. An interval of two weeks between intervention sequences will be

128 incorporated to allow for measurements to be taken and the intervention to be introduced to new

129 clusters.

S/N o.	Cluster	15-19 yrs.	20-24 yrs.	Total AYP	Strata Size	Rando m numbe r	Se q	No. of AYP (n=48 0)
1	Juja	48	98	146	Medium	0.91499	1	186
2	Kiambaa	30	80	110	Medium	0.84210 8	1	
3	Kirinyaga Central	76	83	159	Medium	0.63795 4	1	
4	Kabete	19	75	94	Small	0.96930	1	
5	Kirinyaga South	27	48	75	Small	0.83271 2	1	
6	Ruiru	77	253	330	Large	0.72523	1	
7	Gatundu South	75	91	166	Medium	0.55584 9	2	170
8	Gatundu North	52	55	107	Medium	0.54669 6	2	
9	Limuru	41	62	103	Medium	0.54129 6	2	
10	Lari	12	23	35	Small	0.70153 9	2	
11	Kirinyaga East	29	26	55	Small	0.56774 9	2	
12	Thika Level 5	172	196	368	Large	0.22612 7	2	
13	Githunguri	45	56	101	Medium	0.45808	3	124
14	Thika Town	102	135	237	Medium	0.37940 2	3	
15	Kiambu Township	87	112	199	Medium	0.06299 9	3	
16	Kirinyaga West	29	42	71	Small	0.51488 6	3	

131 Justification of stepped wedge design

132 The stepped wedge design was chosen as individual randomization into control and the patient

133 portal within a facility would inevitably lead to contamination as the control group would

inadvertently be exposed to the intervention. The staggered approach to implementation alsoallows for enhancements to the portal based on lessons learned from preceding clusters.

136 **Study population**

137 In our study, the intervention will be targeted at clusters, where a cluster is defined as a group of 138 EMR-capable facilities in geographical proximity. Outcome parameters will be determined at 139 patient level. Two key strategies will be employed to recruit participants into the study. A line 140 listing of all AYP in the participating EMR sites will be done from the central EMR database and 141 random number sequences used to select eligible participants per facility with allowance made 142 for refusals. Selected participants will then be invited for an open day activity during which 143 recruitment will be done after obtaining informed consent. Weekly appointment diaries will also 144 be used to line list AYP due for their clinic visit in the coming week with a random number 145 sequence generated and applied to select eligible participants. These strategies will be 146 undertaken repeatedly until the required sample size is obtained. Measurements will be taken on 147 the same cohort and by the same observer at the end of each successive step when a cluster 148 moves from control to the active intervention (table 2).

149 Intervention

myCareHub[™] will be available on google play-store and iOS app-store. The portal has been
developed by the study team with significant input from end users and is designed to offer
several functionalities critical for catalysing the behaviour change process as per the COM-B
framework (figs 2&3). The portal will comprise two mobile based applications: a patient portal
and a health care provider (HCP) portal. Features available to patients will include e-learning
resources in text, audio, videos and other media, focussing on HIV treatment literacy, disclosure

156 support, adherence support, sexual and reproductive health (SRH) and coping skills; online 157 communities for peer-to-peer networking and learning; an online patient diary to support self-158 monitoring by enabling patients to view their medical data from the facility based EMR and to 159 record and share their experiences with HCPs; online based web forms and survey tools to 160 capture patient reported outcomes which will trigger a service request on the HCP portal so that 161 care can be personalised and offered without delay; in app and short message service (sms) 162 notifications for appointments and other reminders; and a mechanism for appointment 163 rescheduling (to be developed in the second phase). The HCP portal will enable providers to 164 track and monitor patient treatment, adherence, and symptoms, and to provide personalised care 165 based on response data from the patient diary. As the apps are linked and synchronised with the 166 facility EMR, HCPs can capture and access longitudinal patient level visit data and other medical 167 information such as laboratory investigation reports. On a quarterly basis, open forums will be 168 conducted with portal users - HCPs and patients, to ensure they can access and use all the 169 available features and to capture qualitative end-user insights.

170 **Outcome parameters**

Outcome parameters will be measured in individuals at pre-specified time points, baseline, every3 months, and end-line (table 5), using digitised case report forms.

173 Table 5: Outcome variables

Variable	Definition	Units	Instrument/sourc e	Measuremen t level	Measuremen t period	Compariso n Groups	Analysis
PAM	Patient activation measure	100-point scale	PAM-13	Individual	Baseline, 3Mo, 6 Mo, 9Mo	Intervention vs. control	Mean change in PAM in the Intervention vs. control
Self-reported Medication adherence	Estimate of adherence on 0-100% scale	Proportion	Visual analogue scale and adherence questionnaire	Individual	Baseline, 3 Mo, 6 Mo, 9 Mo	Intervention vs. control	% Adherence Int. vs. control
VL suppression (VLS)	Dichotomous , suppressed (below low limit of detection, LDL) vs. not suppressed (above LDL)	Suppressed/ not suppressed	EMR record	Individual	Baseline, 3 Mo, 6 Mo, 9 Mo	Intervention vs. control	% VLS intervention vs. control
Cluster retention	Active in care at the end of reporting period/active at the beginning of the period*100	Proportion	Routine program data	Cluster	Baseline, 3Mo, 6Mo, 9Mo	Intervention vs. control	% Retention intervention vs. control
Cluster VLS	Percent viral load suppression	Proportion	Routine program data	Cluster	Baseline, 3Mo, 6Mo, 9Mo	Intervention vs. control	% VLS intervention vs. control

	within cluster						
Mobile health application Usability Score	Numerical score: More being more usable	Mean score	MAUQ mHealth App Usability Questionnaire (MAUQ) for Interactive mHealth Apps Used by Patients & HCPs	Individual	End-line	Intervention	Mean score by baseline characteristics
Acceptability score	Mixed tool: Likert-like Scale and text	sub-section scores	Custom acceptability tool	Individual	End-line	Intervention	Mean scores by baseline characteristics
TB case finding	Screening 4 questions each score 0 or 1. Total score 4	0-4	Portal TB case finding tool Paper-based TB case finding tool	Individual	continuous	Intervention vs. program	 Proportion of participants who reported 3 out of 4 symptoms on the portal. and % of these who reported to the facility for further evaluation and % of these with confirmed TB % of total TB cases that were

							were identified through portal - [Total # of depression cases identified through the portal during study
							duration/ Total # of depression cases identified overall (portal + standard of care) during the same duration]
Contraceptiv e use intention screening	4 questions on contraceptive use desire and eligibility	LMP Y/N to pregnancy Y/N to using or desiring contraceptive s	Portal incorporated contraceptive use intention screening tool	Individual	continuous	intervention	*100 Proportion users eligible for contraceptive s and successfully referred % All contraceptive uptake requested from portal -

						[Total # of contraceptive uptake requests from portal during study duration/ Total # of contraceptive uptake requests overall (portal + standard of care) during the same duration] *100
Sexual and Gender Based Violence (SGBV) screening	4 questions Y/N screening for emotional. Physical, sexual, and intimate partner violence; each has either Y/N answer	Portal incorporated SGBV screening tool	Individual	continuous	intervention	% Survivors successfully identified & referred % Total SGBV cases reported through portal - [Total # of SGBV cases reported through the portal during the study duration/

							Total # of SGBV cases reported overall;(portal + standard of care) during the same duration] *100
Alcohol and substance use disorder screening	Six questions, 2 or more affirmative answers indicating alcohol or drug use problem	Y/N	Portal incorporated CRAFFT tool	Individual	continuous	intervention	% Youth with disorder successfully identified & referred % Of total identified originating from portal - [Total # of youth identified with the disorder through the portal during the study duration/Total # of youth identified with the disorder overall (portal

							+ standard of care) during the same duration] *100
Social engagement	Six questions on social supporters	Names of supporters and ratings of support	SSQ-6 at baseline Online communities' engagement metrics	Individual	Baseline, continuous	n/a	Engagement in communities' vs baseline engagement

174	The primary	y outcome will be chan	nge in natient	activation measure	(PAM)) at 6 and 9 months
1/4	The primary	y outcome will be cha	nge in patient	activation measure		at 0 and 7 months.

175 Secondary outcomes will include self-reported adherence (months 3,6 &9) and latest viral load.

176 **Portal-based measures**

- 177 Portal-based measures will include portal functionality, quality, fidelity, and an estimate of total
- 178 cost in setting up the portal. Four key elements of the patient diary screening for Tuberculosis
- 179 (TB) and sexual and gender-based violence (SGBV), contraceptive needs assessment and
- 180 screening for alcohol and substance use disorders will be monitored, and the time taken for HCPs
- 181 to resolve service requests recorded and compared to usual non-portal based clinical practice. An
- analytical dashboard will be developed to provide real time updates on portal engagement
- 183 metrics.

184 **Evaluating Usability**

- 185 Participation in online communities will be tracked and compared with baseline social
- 186 engagement score (SES).
- 187 During the study, focus group discussions (FGDs) will be used to elicit insights into the client
- 188 experience of the portal that will go towards future enhancements.
- 189 A mobile health app usability survey (MAUQ patient and health care provider) and an
- 190 acceptability survey will be administered at the end of the intervention period.

191 Statistical methods

- 192 Baseline participant characteristics i.e., sociodemographic (age, sex, occupation) and clinical
- 193 information (duration on ART, presence of treatment buddy and last viral load) will be described
- 194 by cluster.

The primary outcome will be analysed as mean PAM/ change in PAM score between
intervention and control groups at 6 and 9 months by age category (15-19 vs. 20-24), sex (male
vs. female) and duration on ART (<12 months and >12 months). PAM total scores of 0 and 100
will be considered as missing data and PAM changes will be analysed over time and across PAM
levels as per the developer's recommendations.

200 Statistical analysis of the primary and secondary endpoints will be conducted in either R or SAS

201 using generalised linear mixed models which allow for incorporation of correlations due to

202 repeated measures, cluster effects and potential time effects. Sensitivity analyses, including use

203 of causal inference methods, will be conducted to assess the effect of differential patient and/or


204 cluster characteristics over time and/or attrition on the comparison between intervention periods.

Thematic analysis will be conducted on qualitative insights from FGDs, and the operational and other costs related to running the portal tracked to facilitate cost analysis.

207 Sample size

208 The primary outcome will be a change in patient activation measure (PAM) (Hibbard JH, et al, 209 2004). Lin and co-authors found an average effect size of 0.33 in a meta-analysis on studies 210 involving patients with chronic disease reporting change in PAM (Lin et al., 2020). Also, a 211 difference of 4 points on the PAM scale is considered clinically important and Marshal et al were 212 able to demonstrate that a 5-point difference was significantly associated with higher odds of 213 CD4 count>200, retention, and viral load suppression (J. H. Hibbard & Tusler, 2007; Rebecca 214 Marshall et al., 2013). Following the definitions as outlined in Hooper et al., 2006, assuming an 215 intra- cluster correlation of 0.02 and individual autocorrelation of 0.8, and only low "time by 216 cluster" effects impacting the PAM scores, the study will require a minimum sample size of 27

- 217 per cluster to demonstrate a change of 5 point (green lines in figure 5) in the activation score
- between the two groups, assuming the same standard deviation as in Marshall, Beach (10) with a
- 219 power of at least 90% at an alpha of 0.05% (11).
- 220 Figure 5: Sample size estimation for stepped wedge design



221

222 It is worth noting that the power to demonstrate a difference will be affected substantially by the 223 cluster by time effect. Hemming et al. provided minimal guidance – but did mention a range on 224 that correlation between 0.3 (large effect) to 0.9 (small effect). They strongly suggest a 225 sensitivity analysis on these assumptions, which is provided in Figure 5. Focusing on the green 226 lines, in the presence of high intra-participant variability but small time by cluster effects, 227 approximately 90% power can be attained with 22 participants per cluster. However, if the time 228 by cluster effect is stronger, power to demonstrate 5 points change drops to 80%. A 10% increase 229 in sample size will be added to account for non-participation, requiring a total of 30 participants

per cluster. Based on the above assumptions, the total minimum sample size is therefore
estimated at 30*16=480. The number of participants lost to follow-up will be monitored
throughout the study, and mitigation strategies implemented to accommodate any unforeseen
impact by additional recruitment of patients. To compute the sample size for each site, a
weighting based on the total AYP will be used. The following formula will be used to obtain a
sample for each of the study sites.

$$n_i = \frac{N_i}{N}$$

where, n_i = Sample size for site *i*, N_i = total AYP in site *i* and N = total AYP in all the study sites

238 Ethical approval

239 The AMREF Health Africa Ethics & Scientific Review Committee (ESRC) and the respective 240 County Health Departments have both sanctioned this protocol. Every participant involved 241 provided their informed and written consent. For participants aged between 15 to 17 years, the 242 study investigators were granted a waiver for parental consent by the Ethics and Scientific 243 Review Committee (ESRC). This decision was based on several considerations: to avoid 244 unintentional revelation of the HIV status, to enhance the participation rate, and to mitigate 245 selection bias, especially since the study entailed minimal risk to its participants. Furthermore, 246 the National Commission for Science, Technology, and Innovation (NACOSTI) has provided a 247 research license permitting the execution of the study. Additionally, this trial has been 248 catalogued in the Pan African Clinical Trial Registry at www.pactr.org with the distinctive ID: 249 PACTR202303729957231.

250 **Dissemination of results**

- 251 Research results will be disseminated via stakeholder forums, scientific conferences, research
- 252 publications and the media.

253 Study limitations

254 The experience of end-users of the portal may be affected by loss of smartphones or internet

- 255 bundles. Application builds may be unstable on various operating system (OS) versions despite
- round the clock efforts to identify and mitigate these hurdles. Network and power outages may
- 257 limit access to the portal as well as integration of portal and EMR. These challenges might result
- in lower-than-anticipated levels of patient activation from the intervention.

Discussion and Implications

To our knowledge, this is the first study of its kind in Kenya to explore the utility of a smart phone-based application on patient activation among AYP living with HIV. By engaging this tech-savvy sub-population that has been shown to have unique needs as equal partners in their wellness journey through myCareHub®, the study will provide a blue-print that could be applicable to other diseases and sub-populations, more so as features of the intervention itself such as quality, fidelity and usability will be documented.

266 List of References

267 1. UNICEF. HIV and AIDS. Protecting children and adolescents from HIV and AIDS and268 providing care. 2021.

269 2. Bekker LG, Hosek S. HIV and adolescents: focus on young key populations: J Int AIDS
270 Soc. 2015 Feb 26;18(2Suppl 1). doi: 10.7448/IAS.18.2.20076. eCollection 2015.

271 3. UNAIDS. AIDSinfo global data on HIV epidemiology and response. 2020.

4. Kemp S. Digital 2021 Kenya2021 14th September 2023. Available from:
 https://datareportal.com/reports/digital-2021-kenya?rq=kenya.

5. Nations U. YouthStats: Information and communication technology. . 2022.

275 6. Jongbloed K, Parmar S, van der Kop M, Spittal PM, Lester RT. Recent Evidence for
276 Emerging Digital Technologies to Support Global HIV Engagement in Care. Curr HIV/AIDS
277 Rep. 2015;12(4):451-61.

278 7. Otte-Trojel T, de Bont A, Rundall TG, van de Klundert J. How outcomes are achieved
279 through patient portals: a realist review. Journal of the American Medical Informatics
280 Association : JAMIA. 2014;21(4):751-7.

281 8. West R, Michie S. A brief introduction to the COM-B Model of behaviour and the
282 PRIME Theory of motivation. Qeios. 2020.

283 9. WHO. Monitoring and evaluating digital health interventions: a practical guide to284 conducting research and assessment. Geneva2016.

10. Marshall R, Beach MC, Saha S, Mori T, Loveless MO, Hibbard JH, et al. Patient
activation and improved outcomes in HIV-infected patients. J Gen Intern Med. 2013;28(5):66874.

11. Hemming K, Kasza J, Hooper R, Forbes A, Taljaard M. A tutorial on sample size
calculation for multiple-period cluster randomized parallel, cross-over and stepped-wedge trials
using the Shiny CRT Calculator. Int J Epidemiol. 2020;49(3):979-95.